Business
New data shows higher efficacy rate for Pfizer and BioNTech coronavirus vaccine candidate // Motley Fool Australia
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
On Wednesday morning, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) presented new data from a final efficacy analysis on their BNT162b2 vaccine candidate, and the news was very good.
In a joint press release, the 2 partners said the vaccine met all of its primary efficacy endpoints. Better still, it had an efficacy rate of 95% in participants both with and without prior coronavirus infection (mild or severe). Also, the vaccine’s efficacy was consistent across key demographics such as age, gender, and ethnicity. No serious safety concerns were reported.
That rate, meanwhile, is higher than the 90%-plus demonstrated in the…
-
General20 hours agoFrom Humpty Doo to the bush, these voters’ views reflect the challenge for federal politicians
-
Noosa News20 hours agoThe Pedro Pascal-Led Fantastic Four Face Julia Garner’s Silver Surfer in the New Full ‘First Steps’ Trailer
-
Noosa News24 hours agoMeet Llew O’Brien, LNP | Noosa Today
-
Noosa News16 hours agoFrom Dreamy Dining Rooms to Moody Basement Bars, Nearly 200 Venues Have Been Shortlisted for the 2025 Australian Interior Design Awards